PROJECT

Projects

Summary of Investment Information

Project Number

48298

Company Name

3SBio Inc.

Date SPI Disclosed

Dec 17, 2024

Country

China

Region

East Asia and the Pacific

Projected Board Date

Mar 18, 2024

Environmental Category

B - Limited

Status

Active

Last Updated Date

Oct 25, 2025

Department

CM4S2 - Regional Industry - MAS Asia & Pac/MAS Services, EAP

Industry

other

Previous Events

Approved : Mar 18, 2024
Signed : May 10, 2024
Invested : Oct 21, 2025

Sector

other

Project Description

 Founded in 1993 and headquartered in Liaoning, 3SBio Inc. (“3SBio” or the “Company”) is a pioneer in the Chinese biotechnology industry that is primarily involved in the development of biopharmaceutical products to meet significant unmet medical needs in the areas of cancer and its supportive care, nephrology and other diseases or conditions.

The proposed investment will support 3SBio to fund: (i) the expansion of its research and manufacturing facilities in Liaoning Province, a frontier province in Northern China, and Guangdong Province; and (ii) Company’s expansion overseas in emerging market (the “Project”). The Project is expected to support the improved access to innovative, yet affordable, biopharmaceutical products in China and other developing nations.                                                    

Sponsor / Cost / Location

Development Impact

E&S Category Rationale / Risks and Mitigation